PL1636593T3 - Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met. - Google Patents

Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met.

Info

Publication number
PL1636593T3
PL1636593T3 PL04754499T PL04754499T PL1636593T3 PL 1636593 T3 PL1636593 T3 PL 1636593T3 PL 04754499 T PL04754499 T PL 04754499T PL 04754499 T PL04754499 T PL 04754499T PL 1636593 T3 PL1636593 T3 PL 1636593T3
Authority
PL
Poland
Prior art keywords
met
modulating
interaction
beta chain
hgf
Prior art date
Application number
PL04754499T
Other languages
English (en)
Inventor
Daniel K Kirchhofer
Robert A Lazarus
Xiaoyi Yao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33555430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1636593(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PL1636593T3 publication Critical patent/PL1636593T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL04754499T 2003-06-06 2004-06-04 Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met. PL1636593T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47677803P 2003-06-06 2003-06-06
US53211703P 2003-12-23 2003-12-23
PCT/US2004/017901 WO2005001486A1 (en) 2003-06-06 2004-06-04 Modulating the interaction between hgf beta chain and c-met
EP04754499A EP1636593B9 (en) 2003-06-06 2004-06-04 Modulating the interaction between hgf beta chain and c-met

Publications (1)

Publication Number Publication Date
PL1636593T3 true PL1636593T3 (pl) 2009-08-31

Family

ID=33555430

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04754499T PL1636593T3 (pl) 2003-06-06 2004-06-04 Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met.

Country Status (16)

Country Link
US (8) US20060035278A9 (pl)
EP (3) EP2093570A1 (pl)
JP (1) JP2007526447A (pl)
KR (2) KR101148657B1 (pl)
AT (1) ATE425463T1 (pl)
AU (1) AU2004252475A1 (pl)
CA (1) CA2528343A1 (pl)
DE (1) DE602004019919D1 (pl)
DK (1) DK1636593T5 (pl)
ES (1) ES2323425T3 (pl)
HR (1) HRP20090324T1 (pl)
MX (1) MXPA05013181A (pl)
PL (1) PL1636593T3 (pl)
PT (1) PT1636593E (pl)
SI (1) SI1636593T1 (pl)
WO (1) WO2005001486A1 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
JP2008516629A (ja) 2004-10-20 2008-05-22 ペアス インスティテュート アーベー 肝細胞増殖因子（ｈｇｆ）の生物活性に関する評価
DK1846406T5 (da) 2005-02-09 2011-10-31 Arqule Inc Maleimidderivater, farmaceutiske sammensætninger og fremgangsmåder til behandling af cancer
MX2007011650A (es) * 2005-03-25 2008-01-16 Genentech Inc Mutaciones de la c-met en el cancer del pulmon.
CN101184506B (zh) * 2005-03-25 2013-07-17 健泰科生物技术公司 用于调节超稳定化的c-met的方法和组合物
ZA200710599B (en) 2005-04-15 2009-08-26 Genentech Inc HGF Beta chain variants
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US20110053931A1 (en) * 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
MY183404A (en) 2006-12-19 2021-02-18 Genentech Inc Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
CA2690799C (en) 2007-06-22 2015-06-16 Arqule, Inc. Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
JP5490688B2 (ja) 2007-06-22 2014-05-14 アークル インコーポレイテッド 癌の治療のためのインドリルピロリジン
CN101801937A (zh) 2007-06-22 2010-08-11 艾科尔公司 喹唑啉酮化合物及其使用方法
US8247374B2 (en) * 2007-11-09 2012-08-21 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
MX2010009669A (es) * 2008-03-06 2010-09-22 Genentech Inc Terapia de combinacion con antagonistas de c-met y egfr.
EP2446274B1 (en) * 2009-06-26 2017-08-09 PEAS Institut AB Method for determining biologically active hgf
BR112012009412A2 (pt) 2009-10-22 2016-11-29 Genentech Inc 'anticorpo anti-hepsina isolado, molécula de ácido nucleico, célula hospedeira, método para fabricar um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo e método para fabricar um anticorpo anti-serina protease'
WO2011110642A2 (en) 2010-03-10 2011-09-15 Genmab A/S Monoclonal antibodies against c-met
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CN102643268B (zh) 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
WO2013143376A1 (zh) 2012-03-26 2013-10-03 武汉盛云生物医药科技有限责任公司 含1，2，4-三嗪-3，5-二酮的喹啉类化合物及其应用
ES2738310T3 (es) 2012-10-12 2020-01-21 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2016149265A1 (en) 2015-03-16 2016-09-22 Kolltan Pharmaceuticals, Inc. Anti-met antibodies and methods of use thereof
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
JP7380999B2 (ja) * 2018-09-06 2023-11-15 国立大学法人 東京大学 環状ペプチド
JP7750828B2 (ja) 2019-09-16 2025-10-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
ATE155525T1 (de) * 1991-05-10 1997-08-15 Pharmacia & Upjohn Spa Verkürzte formen den hepatozyten wachstumsfaktor (hgf) rezeptors
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5328837A (en) * 1992-05-18 1994-07-12 Genentech, Inc. Hepatocyte growth factor protease domain variants
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
DK0674506T3 (da) 1992-12-02 2001-01-08 Alkermes Inc Væksthormonholdige mikrosfærer med styret frigivelse
DE69519382T3 (de) 1994-09-09 2008-09-18 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5647409A (en) 1995-04-04 1997-07-15 Allergan On-site syringe filling apparatus for viscoelastic materials, and corresponding method for on-site syringe filling
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
WO1996040072A2 (en) 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US5911252A (en) 1997-04-29 1999-06-15 Cassel; Douglas Automated syringe filling system for radiographic contrast agents and other injectable substances
US6677377B2 (en) * 2000-06-21 2004-01-13 Georgetown University School Of Medicine Structure based discovery of inhibitors of matriptase for the treatment of cancer and other conditions

Also Published As

Publication number Publication date
CA2528343A1 (en) 2005-01-06
ES2323425T3 (es) 2009-07-15
US20150126448A1 (en) 2015-05-07
MXPA05013181A (es) 2006-06-23
HK1092872A1 (zh) 2007-02-16
EP1636593B9 (en) 2009-12-16
US20170106042A1 (en) 2017-04-20
DK1636593T5 (da) 2009-07-27
EP2093570A1 (en) 2009-08-26
US20050037431A1 (en) 2005-02-17
US20070129301A1 (en) 2007-06-07
ATE425463T1 (de) 2009-03-15
KR20110117728A (ko) 2011-10-27
US20060035278A9 (en) 2006-02-16
AU2004252475A1 (en) 2005-01-06
SI1636593T1 (sl) 2009-08-31
US20130143813A1 (en) 2013-06-06
KR101148657B1 (ko) 2012-07-05
US20110177058A1 (en) 2011-07-21
EP2367008A2 (en) 2011-09-21
WO2005001486A1 (en) 2005-01-06
US20100040634A1 (en) 2010-02-18
PT1636593E (pt) 2009-06-03
JP2007526447A (ja) 2007-09-13
DK1636593T3 (da) 2009-06-15
EP1636593A1 (en) 2006-03-22
EP2367008A3 (en) 2014-12-24
DE602004019919D1 (de) 2009-04-23
HRP20090324T1 (hr) 2010-02-28
US20190054138A1 (en) 2019-02-21
EP1636593B1 (en) 2009-03-11
KR20060017634A (ko) 2006-02-24

Similar Documents

Publication Publication Date Title
SI1636593T1 (sl) Moduliranje interakcije med beta-verigo HGF in c-met
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
DK1644336T3 (da) Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
IL175885A0 (en) Monovalent antibody fragments useful as therapeutics
WO2005044976A3 (en) Oligomeric compounds for use in gene modulation
NO20041917L (no) Spesifikke midler som binder humant angiopoietin-2
TW200510303A (en) Novel compounds
PL371464A1 (pl) 3-Alkilowane 5,5',6,6',7,7',8,8'-oktahydro-2,2'-binaftole i 3,3'-dialkilowane 5,5',6,6',7,7',8,8'-oktahydro-2,2'-binaftole oraz sposoby ich wytwarzania
MXPA00007388A (es) Metodos para tratar la pigmentacion de la piel.
MY139523A (en) Ziprasidone composition and synthetic controls
ZA200705177B (en) Lyophilization of virosomes
TNSN07222A1 (en) Nematicidal compositions
BRPI0413924A (pt) composições antiperspirantes estabilizadas contendo produtos de soja
DK1560812T3 (da) Aminocyclohexyletherforbindelser og anvendelser deraf
SI1373503T1 (sl) Nevtroficni dejavniki
MXPA05013251A (es) Composiciones para estado de oxigeno mejorado en animales de compania.
ATE430127T1 (de) Hif hydroxylase-inhibitoren zur anämiebehandlung
DE50204688D1 (de) N-alkylaziridinoprepolymere als dentalmasse
NO20024535L (no) Ventilasjonsventilsammensetning for stöpeformer
PL1680430T3 (pl) Sposoby wytwarzania postaci i (s)-(+)-wodorosiarczanu klopidogrelu
WO2005107461A8 (en) Modulating lymphatic function
TW200621853A (en) Resin composition
ATE400273T1 (de) 1-2'-(1,4'-biperidin-1'-yl)-1-(phenyl)- ethylcyclohexanol-derivate als monoamin- wiederaufnahme-modulatoren zur behandlung von vasomotorischen symptomen
ES2173862T3 (es) Ligandos de aminocarboxilato que tienen restos amidicos aromaticos sustituidos.